Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 14.50 14.00 15.00 15.12 14.50 14.50 88,057 08:00:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.1 -4.4 - 36

Futura Medical Share Discussion Threads

Showing 16926 to 16943 of 19725 messages
Chat Pages: Latest  681  680  679  678  677  676  675  674  673  672  671  670  Older
DateSubjectAuthorDiscuss
02/7/2019
10:19
large trade in the states (famdf)
mikethebike4
02/7/2019
08:34
The markets that Futura's ED and topical pain gels are targeting, are in excess of $12 billion pa. If they only get a small market share with 15% royalties,the numbers are massive. On top of that the previous broker had factored in a total of $90 million in upfront and milestone payments for the med gel.
j777j
02/7/2019
08:12
seen this today hxxps://www.pro activeinvestors.co.uk/companies/stocktube/13946/futura-medical-plc---elevator-pitch-13946.html
jaws6
01/7/2019
12:41
The game changer is that the TPR pain gels penetrate up to 10 times faster that currently available drugs. This means not only do they work much faster but should enable the application to be cut from say 4xday to 2x day.
j777j
01/7/2019
12:19
J777J 'I agree and it is actually twice the size of the ED market.' I'm not too surprised by that. Arthritis of the knee, say, not bad enough for an op, or maybe the patient too unfit for surgery, but very debilitating and painful. Lots of potentially very unpleasant side effects, some very serious, from oral NSAIDs. Try morphine or similar instead? again side effects are marked and of course they're addictive. So an effective topical NSAID such as TPR100, with reduced risk of systemic side effects, will be a valuable and welcome addition to the therapeutic armoury.
rrr
01/7/2019
12:11
That was on top of $75 million paid upfront after only a phase 2 study. "Lilly agreed to pay Icos, a biotechnology start-up company that owns the rights to the drug, an up-front fee of $75 million. Analysts said that amount was extremely high for a drug that had not yet entered the final, and most important, phase of clinical trials. In another unusual arrangement, the two companies will share the marketing and sales of the drug in North America and in Europe and split the profits 50-50."
j777j
01/7/2019
10:58
I agree and it is actually twice the size of the ED market. Liberum did not even include it in their last report. Topical Pain Relief Market to Reach $13.27 Bn, Globally, by 2025 Increase in geriatric population, rise in prevalence of arthritis, high demand from athletes, and lesser side effects as compared to conventional oral medicines facilitate the growth in the global topical pain relief industry. Non-opioids segment is likely to be lucrative from 2018 to 2025. Over-the-counter pain relief segment to lead in terms of revenue and growth by 2025. E-commerce segment to register the highest growth rate by 2025. Asia-Pacific to grow the fastest during the forecast period
j777j
01/7/2019
10:20
Don't forget TPR100: TPR100 - Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism Marketing authorisation application by UK commercialisation partner, Thornton & Ross (a subsidiary of STADA AG) submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2018. Ongoing commercial discussions with several potential distribution partners for other territories. Any further licensing deals are expected to be after UK regulatory approval. TPR100 - Post year end Supporting Thornton & Ross on responses to initial MHRA feedback received in February 2019. hTTps://www.futuramedical.com/content/news/archive19/100419.asp
rrr
01/7/2019
09:57
I meant over the next day or two.
tiananmen
01/7/2019
09:35
I am particularly interested in the 56p level,where a lot of investors bought shares.
j777j
01/7/2019
09:31
44p target next
tiananmen
01/7/2019
08:26
Huge and growing marketplace. Where viagra at launch became the fastest prescription product ever launched. Med2005 works in 5 to 10 mins v up to one hour. Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024: Zion Market Research According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024. Inetresting to note how much larger the market is (double the size,) according to independent research is,compared to the Liberum forecast where the see 140p as level if trials are complete success. So that number could turn out to be conservative.
j777j
01/7/2019
08:04
No matter how much medication is applied at some point it will loose its effectiveness.
glavey
01/7/2019
07:42
Interestingly the share price is still 60% below 2016 levels and yet they are within 12 weeks of phase 3 results.
j777j
28/6/2019
19:19
From 7p to 35p in eight months, and now half way to being a ten bagger.
swiftnick
28/6/2019
12:40
TPR100 approval stock will hit £1+ and with positive Phase readout of MED stock will explode to £3+ and its highly likely that results will be positive .. STRONG BUYYYYYYYYYYYYYYYYYYY love it
ih_116147
28/6/2019
11:18
When you factor in the Liberum report's numbers are significantly less than Futura's 2 independent reseach forecasts indicating around $1.4 peak sales. The upside they have, could well turn out to be a low ball number. Why on earth risk taking a pill when you can apply a much faster a safer topical gel? This is disruptive technology. When the Ceo is telling us that as of yesterday they have had huge interest,makes me think he is speaking to long suffering shareholders.
j777j
28/6/2019
10:10
That's a load of potential upside from the current price.
cf456
Chat Pages: Latest  681  680  679  678  677  676  675  674  673  672  671  670  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 03:19:57